Drug Trial Radar · NCT01120418
Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
Last checked: Nov 20, 2026Latest source record: Aug 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
May 2007
Primary completion
Oct 2007
Study completion Feb 2008
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the effect on corneal endothelial cell density changes when ISV-403 is administered for five (5) days compared to no drug treatment, in healthy subjects.
Conditions
- Healthy
Interventions
Besifloxacin Ophthalmic Suspension 0.6%Drug
administered 3 times a day for 5 days to one eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endothelial cell density change between treatment group.Time frame: Baseline, 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.